https://www.selleckchem.com/products/cc-90001.html
We found a significant improvement in the accuracy of bilirubin risk level documentation, with a reduction in erroneous risk stratification from 4% (15/232) to 0.4% (1/243), p less then 0.001. We did not find significant a difference in erroneous documentation of the bilirubin lab value (p = 0.07). CONCLUSIONS Integrating the neonatal hyperbilirubinemia risk assessment process into the EHR may reduce errors and improve provider documentation and adherence to recommended guidelines. A novel series of 4-(3-(difluorophenyl)-5-(dimethoxyph
Curtir
Comentario
Compartilhar
